AstraZeneca wins three business development awards at 10th Annual Scrip Awards 2014


Monday, 8 December 2014

AstraZeneca won three Scrip Awards at the 10th Annual Scrip Awards 2014, held in London, in the following categories: Best Partnership Alliance, Best Licensing Deal of the Year, and Best Management Team of the Year 2014.

The Best Partnership Alliance 2014 award recognized the oncology collaboration between MedImmune and Immunocore to research and develop novel cancer therapies using Immunocore’s proprietary ImmTAC technology. Receiving the award on behalf of MedImmune, Reg Seeto, Head, Biotech Partnering & Strategy said, “the combined research and development strengths of the Immunocore and MedImmune alliance provide a unique opportunity to unlock the potential of ImmTACs for the benefit of cancer patients worldwide across a range of cancer types.”

Eva-Lotta Allan, Chief Business Officer, Immunocore, said, ”We are delighted to have won the SCRIP Award 2014 together with our partner MedImmune for the Best Partnership Alliance. It is a pleasure to work with the MedImmune team and we look forward to together advancing ImmTAC’s towards the clinic.”

The Best Licensing Deal of the Year award was awarded to AstraZeneca for the acquisition of Bristol-Myers Squibb’s interest in the joint diabetes alliance. Receiving the award, Jo Kelley, VP, Business Development Operations (UK), said ”We’re delighted that the judges acknowledged the complexity and strategic importance of the transaction and also the remarkable speed at which the deal was executed by the AstraZeneca and Bristol-Myers Squibb teams.”

The Best Management Team of the Year was awarded to the AstraZeneca Business Development Operations (BDO) Leadership Team for the strategic contribution that business development has played in 2014 to support therapeutic areas and the business.

On receiving the award on behalf of the Leadership Team, Shaun Grady, VP, Business Development Operations, said, ”It’s been an extraordinary year to be in business development at AstraZeneca considering the volume of deal flow, the scale of transactions, and the speed at which the team has delivered - all happening during one of the most significant moments in our corporate history.”



  • Partnering